{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:42:34Z","timestamp":1790811754176,"version":"4.1.0"},"reference-count":56,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,7,15]]},"abstract":"<jats:p>The development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the right target antigen was a critical part of the process. CD38 as a target has been considered for some time, but clinically, daratumumab, a CD38 monoclonal antibody, was the first to be tested, and it has delivered the best clinical responses as a single agent to date. Its proven safety and efficacy in combination with other antimyeloma agents have led to several US Food and Drug Administration approvals for treating myeloma. Furthermore, the results of early trials in the induction therapy setting have demonstrated a beneficial role when it is added to the existing induction regimens. This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed\/refractory myeloma and patients with newly diagnosed myeloma.<\/jats:p>","DOI":"10.1002\/cncr.32065","type":"journal-article","created":{"date-parts":[[2019,4,6]],"date-time":"2019-04-06T05:57:26Z","timestamp":1554530246000},"page":"2364-2382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Daratumumab in multiple myeloma"],"prefix":"10.1002","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay K.","family":"Nooka","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4001-9622","authenticated-orcid":false,"given":"Nisha S.","family":"Joseph","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Heffner","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas A.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold C.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Pathology Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Neish","sequence":"additional","affiliation":[{"name":"Department of Pathology Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhav V.","family":"Dhodapkar","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Lonial","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology Winship Cancer Institute, Emory University Atlanta Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(94)90148-1"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.1.395"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1006\/cimm.1996.0267"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483511"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1007813"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2016.03.003"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1813"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506348"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"issue":"1","key":"e_1_2_13_14_1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V130.Suppl_1.838.838","article-title":"Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): PAVO, an open\u2010label, multicenter, dose escalation phase 1b study [abstract]","volume":"130","author":"Chari A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-07-726729"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"issue":"1","key":"e_1_2_13_17_1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V130.Suppl_1.739.739","article-title":"Daratumumab, lenalidomide, and dexamethasone (DRd) versus lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of POLLUX [abstract]","volume":"130","author":"Dimopoulos MA","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-785246"},{"issue":"1","key":"e_1_2_13_19_1","first-page":"1824","article-title":"Daratumumab in combination with pomalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma (RRMM) patients with \u22652 prior lines of therapy: updated analysis of MMY1001 [abstract]","volume":"130","author":"Facon T","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_20_1","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V128.22.492.492","article-title":"Clinical efficacy of daratumumab, pomalidomide and dexamethasone in relapsed, refractory myeloma patients: utility of retreatment with daratumumab among refractory patients [abstract]","volume":"128","author":"Nooka AK","year":"2016","journal-title":"Blood"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"issue":"1","key":"e_1_2_13_22_1","first-page":"3145","article-title":"Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of CASTOR [abstract]","volume":"130","author":"Spencer A","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_23_1","first-page":"1869","article-title":"Daratumumab in combination with carfilzomib and dexamethasone in patients (pts) with relapsed multiple myeloma (MMY1001): an open\u2010label, phase 1b study [abstract]","volume":"130","author":"Lonial S","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_13_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-120737","article-title":"Phase 3 randomized study of daratumumab plus lenalidomide and dexamethasone (D\u2010Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA) [abstract]","volume":"132","author":"Facon T","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_26_1","first-page":"3110","article-title":"Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients with newly diagnosed multiple myeloma (MMY1001): updated results from an open\u2010label, phase 1b study [abstract]","volume":"130","author":"Chari A","year":"2017","journal-title":"Blood"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411321"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-03-1173"},{"issue":"1","key":"e_1_2_13_30_1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood-2018-151","article-title":"Efficacy and updated safety analysis of a safety run\u2010in cohort from GRIFFIN, a phase 2 randomized study of daratumumab (Dara), bortezomib (V), lenalidomide (R), and dexamethasone (D; Dara\u2010Vrd) vs. Vrd in patients (Pts) with newly diagnosed (ND) multiple myeloma (MM) eligible for high\u2010dose therapy (HDT) and autologous stem cell transplantation (ASCT) [abstract]","volume":"132","author":"Voorhees PM","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.577"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0229"},{"key":"e_1_2_13_33_1","unstructured":"Darzalex (daratumumab).https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/761036s004lbl.pdf. Accessed November 6 2018."},{"key":"e_1_2_13_34_1","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1182\/blood.V128.22.2142.2142","article-title":"Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma [abstract]","volume":"128","author":"Chari A","year":"2016","journal-title":"Blood"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2869-4"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0120-2"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1582"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2007.04.001"},{"key":"e_1_2_13_39_1","article-title":"Infectious and immunological sequelae of daratumumab in multiple myeloma [published online July 5, 2018]","author":"Johnsrud AJ","journal-title":"Br J Haematol"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13164"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e20005"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749432"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.13069"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1804751"},{"key":"e_1_2_13_45_1","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1182\/blood.V126.23.3571.3571","article-title":"Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab [abstract]","volume":"126","author":"Chari A","year":"2015","journal-title":"Blood"},{"key":"e_1_2_13_46_1","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1182\/blood.V128.22.2063.2063","article-title":"Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry\u2010developed DIRA test: Hydrashift 2\/4 daratumumab [abstract]","volume":"128","author":"Caillon H","year":"2016","journal-title":"Blood"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2027"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.123"},{"key":"e_1_2_13_51_1","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1182\/blood-2017-03-770776","article-title":"Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab","volume":"129","author":"Garcia\u2010Guerrero E","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_52_1","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1182\/blood-2018-99-117441","article-title":"Immune mediated mechanisms of resistance to daratumumab [abstract]","volume":"132","author":"Viola D","year":"2018","journal-title":"Blood"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-279893"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-809293"},{"issue":"1","key":"e_1_2_13_55_1","first-page":"1819","article-title":"Daratumumab is safe and highly effective in AL amyloidosis [abstract]","volume":"130","author":"Khouri J","year":"2017","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_56_1","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1182\/blood-2018-99-112991","article-title":"Safety, tolerability and response rates of daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a phase II study [abstract]","volume":"132","author":"Sanchorawala V","year":"2018","journal-title":"Blood"},{"issue":"1","key":"e_1_2_13_57_1","first-page":"2009","article-title":"Rapid hematologic and organ responses with daratumumab, bortezomib and dexamethasone in patients with relapsed\/refractory AL amyloidosis [abstract]","volume":"132","author":"Lee SS","year":"2018","journal-title":"Blood"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32065","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.32065","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.32065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:18Z","timestamp":1761871338000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.32065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":56,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2019,7,15]]}},"alternative-id":["10.1002\/cncr.32065"],"URL":"https:\/\/doi.org\/10.1002\/cncr.32065","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"2018-09-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}